Galecto hires new Chief Medical Officer

pharmafile | February 7, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Galecto 

Galecto has announced Bertil Lindmark as their new Chief Medical Officer. He began his posting on 1 February 2020.

Lindmark joins from the eTheRNA immunotherapies, which is a Belgian mRNA immunotherapy company. He has also had an extensive and successful career in the pharmaceutical industry.

Hans Schambye, the Chief Executive Officer of Galecto, said: “We are very please to welcome Bertil to Galecto. His global background, deep scientific knowledge and leadership experience will further strengthen our ambitious targets as we progress GB0139 towards market and explore the potential of our exciting pipeline following the merger with PharmAkea.”

Lindmark was the Global Vice President of Clinical Development for the Respiratory and Inflammation franchises at AstraZeneca. It was here he led the development of Symbicort along with many other gastro-intestinal products. From 2010, he headed Research and Development at Almirall before joining ASLAN pharmaceuticals in Singapore where he focused on atopic skin and lung diseases as well as cancer.

In response to his appointment, Lindmark said: “I look forward to joining Galecto at such an important point in the company’s development. Galecto has a very promising combination of small molecule drug candidates in its pipeline: two targeting the role of galectin-3 in inhibiting cells involved in fibrosis, and one that inhibits LOXL2, a key enzyme involved in the formation of the extracellular matrix during the fibrotic process. These differentiated molecules in clinical phase form a strong foundation on which we aim to build a future global operation.”

Lindmark’s educational background is in medicine and gastroenterology and he obtained a PhD in molecular epidemiology from Lund University in Sweden. He was appointed a visiting professor at Gothenburg University for Innovation and Entrepreneurship at the Institute of Medicine.

Related Content

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …


Japan approves AstraZeneca’s Soliris for paediatric patients with gMG

AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris …

Latest content